Intended to open in 2026, children across Australia and New Zealand who are diagnosed with high-grade brain cancers will have the opportunity to take part in this world-leading international study. TarGeT is an innovative umbrella trial that tests multiple targeted treatments at the same time and uses precision medicine to match therapies to shared genetic features. Its adaptive design allows trial teams to refine treatment arms in real time, helping researchers learn more quickly which approaches show the most promise.
With the support of ANZCHOG, the trial is now preparing to open across hospital sites in both countries. This will expand access to cutting-edge research for families and ensure children can participate regardless of their specific tumour type.
As Professor Nick Gottardo notes, “We urgently need trials like this so we can move quickly to understand which therapies might work for these very hard to treat cancers.”
This progress wouldn’t be possible without our fellow members of the TarGeT Collaborative, a group of remarkable organisations backing this important precision-medicine study:
Robert Connor Dawes (RCD) Foundation, Children’s Cancer Foundation (Australia), My Room Children’s Cancer Charity, The Kids’ Cancer Project, and The Cure Starts Now Cancer Foundation (Australia and US).
A sincere thank you to these partners, and to the dedicated investigators, research teams and hospital staff whose collective effort has brought TarGeT to life and expanded access at two leading paediatric centres.
